A pilot randomized phase II study of adjuvant administration of trastuzumab (Herceptin) versus observation after the completion of adjuvant chemotherapy and radiotherapy in patients with stage I-III breast cancer who have detectable disseminated and/or circulating tumor cells (DTCs and/or CTCs) in the bone marrow or/and the peripheral blood before or/and after the completion of adjuvant treatment

Trial Profile

A pilot randomized phase II study of adjuvant administration of trastuzumab (Herceptin) versus observation after the completion of adjuvant chemotherapy and radiotherapy in patients with stage I-III breast cancer who have detectable disseminated and/or circulating tumor cells (DTCs and/or CTCs) in the bone marrow or/and the peripheral blood before or/and after the completion of adjuvant treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Feb 2012 Results published in Annals of Oncology.
    • 05 Jun 2010 Results presented at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top